Nonalcoholic fatty liver disease (NAFLD ... in reducing the NAFLD-induced inflammation and improving cellular histology. Successful treatment will need to include genetic or molecular-level ...

The prevalence of non-alcoholic fatty liver disease (NAFLD ... In NAFLD-related cirrhosis, liver histology may no longer show inflammation or even steatosis, and this likely represents the ...

Non-alcoholic fatty liver disease (NAFLD) occurs when excess fat accumulates in liver cells in people who consume little or no alcohol. NAFLD is associated with various metabolic risk factors ...

In the ESSENCE trial, semaglutide improved liver fibrosis in patients with metabolic dysfunction-associated steatohepatitis ...

Obesity, alcohol use and other factors are driving up rates of fatty liver disease among American adults, new research warns. By 2018, federal data showed that 42% of adults had some form of fatty ...

Sagimet Biosciences Inc. (Sagimet, Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel therapeutics ...